# Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma

> **NCT00983944** · PHASE2 · WITHDRAWN · sponsor: **Ohio State University Comprehensive Cancer Center**

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** bleomycin sulfate
- **BIOLOGICAL:** rituximab
- **DRUG:** EPOCH regimen
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00983944
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-09
- **Primary completion:** 2011-04-25
- **Final completion:** 2011-04-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Inadequate Accrual
- **Last updated:** 2017-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00983944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00983944, "Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00983944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*